+

WO2002040059A3 - Procedes et compositions pour induire des reponses immunitaires a mediation cellulaire - Google Patents

Procedes et compositions pour induire des reponses immunitaires a mediation cellulaire Download PDF

Info

Publication number
WO2002040059A3
WO2002040059A3 PCT/US2001/045626 US0145626W WO0240059A3 WO 2002040059 A3 WO2002040059 A3 WO 2002040059A3 US 0145626 W US0145626 W US 0145626W WO 0240059 A3 WO0240059 A3 WO 0240059A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
variant
compositions
mediated immune
undesired
Prior art date
Application number
PCT/US2001/045626
Other languages
English (en)
Other versions
WO2002040059A2 (fr
Inventor
Milcho S Mincheff
Dmitri I Loukinov
Seguei Zoubak
Original Assignee
American Foundation For Biolog
Milcho S Mincheff
Dmitri I Loukinov
Seguei Zoubak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Foundation For Biolog, Milcho S Mincheff, Dmitri I Loukinov, Seguei Zoubak filed Critical American Foundation For Biolog
Priority to AU2002239441A priority Critical patent/AU2002239441A1/en
Publication of WO2002040059A2 publication Critical patent/WO2002040059A2/fr
Publication of WO2002040059A3 publication Critical patent/WO2002040059A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés et des compositions destinés à traiter un patient portant des cellules indésirables, par exemple des cellules tumorales ou de cellules infectées par un virus. Le procédé consiste, par exemple, à administrer un polynucléotide codant un variant d'un antigène présent dans la cellule indésirable ('cellule cible'). Le variant n'est pas sécrété par, ni exprimé sur le côté extracellulaire de la membrane cellulaire de, la cellule dans laquelle il est exprimé. De préférence, le variant est biologiquement inactif. L'invention concerne en outre un procédé permettant d'induire une réponse immunitaire à médiation cellulaire contre la cellule indésirable sans pour autant induire une réponse immunitaire humorale. En outre, le procédé est sûr, étant donné que l'absence d'une activité biologique du variant empêche la survenue d'effets délétères chez le patient recevant ledit variant.
PCT/US2001/045626 2000-11-01 2001-11-01 Procedes et compositions pour induire des reponses immunitaires a mediation cellulaire WO2002040059A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002239441A AU2002239441A1 (en) 2000-11-01 2001-11-01 Methods and compositions for inducing cell-mediated immune responses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70423200A 2000-11-01 2000-11-01
US09/704,232 2000-11-01

Publications (2)

Publication Number Publication Date
WO2002040059A2 WO2002040059A2 (fr) 2002-05-23
WO2002040059A3 true WO2002040059A3 (fr) 2003-09-12

Family

ID=24828637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/045626 WO2002040059A2 (fr) 2000-11-01 2001-11-01 Procedes et compositions pour induire des reponses immunitaires a mediation cellulaire

Country Status (2)

Country Link
AU (1) AU2002239441A1 (fr)
WO (1) WO2002040059A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031569A2 (fr) * 2001-10-10 2003-04-17 Centocor, Inc. Vaccins a base d'acides nucleiques utilisant des acides nucleiques codant pour un antigene tumoral et un acide nucleique codant pour un adjuvant cytokine
EP1448588A4 (fr) 2001-10-23 2006-10-25 Psma Dev Company L L C Anticorps et multimeres de proteines psma
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
WO2004092216A1 (fr) * 2003-04-15 2004-10-28 Trangene S.A. Antigene carcino-embryonnaire depourvu de peptide signal, acides nucleiques codant pour celui-ci et une fusion dudit antigene avec un epitope de lymphocytes t, ainsi que leur utilisation pour le traitement et/ou la prophylaxie du cancer
WO2005019464A1 (fr) * 2003-08-21 2005-03-03 Virax Development Pty Ltd Vecteur du poxvirus codant des antigenes specifiques de la prostate pour le traitement du cancer de la prostate
AU2010326174A1 (en) * 2009-12-01 2012-07-12 Medimmune, Llc Improved methods and compositions for detecting and treating CEA-expressing cancers
WO2015143029A1 (fr) * 2014-03-18 2015-09-24 The Johns Hopkins University Système de rapporteur génétique moléculaire à base de psma
WO2017210562A1 (fr) * 2016-06-03 2017-12-07 Etubics Corporation Compositions et méthodes de vaccination anti-tumorale utilisant des antigènes associés au cancer de la prostate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045444A1 (fr) * 1997-04-10 1998-10-15 The Regents Of The University Of California Vaccins avec transformation intracellulaire accrue
WO2000014257A1 (fr) * 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045444A1 (fr) * 1997-04-10 1998-10-15 The Regents Of The University Of California Vaccins avec transformation intracellulaire accrue
WO2000014257A1 (fr) * 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KANO M ET AL: "Induction of SIV-specific immune responses by using recombinant sendai viral vector", CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS, XX, XX, PAGE(S) 1, XP002212654 *
LUBAROFF D M ET AL, THE JOURNAL OF UROLOGY, vol. 159, no. 5, 31 May 1998 (1998-05-31), pages 9, XP009002633 *

Also Published As

Publication number Publication date
WO2002040059A2 (fr) 2002-05-23
AU2002239441A1 (en) 2002-05-27

Similar Documents

Publication Publication Date Title
AU6117696A (en) Nucleic acid respiratory syncytial virus vaccines
AU1026692A (en) Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
WO1999044636A3 (fr) Renforcement des reponses immunitaires vis a vis d'antigenes independants de t
AU4322996A (en) Variants of human papilloma virus antigens
PL346299A1 (en) Method of dna vaccination
WO1999029341A3 (fr) PROCEDES PERMETTANT DE RENFORCER DES REPONSES IMMUNITAIRES DE PROTECTION AU MOYEN DE POLYPEPTIDES $i(LEISHMANIA)
NO960309L (no) Agonister og antagonister for humaninterleukin-10
EP0658623A3 (fr) Virus d'Herpes attenués, virus d'herpes comprenant de l'ADN étranger codante pour une séquence d'acides aminés, et vaccins les contenant.
WO2002024234A3 (fr) Utilisation de vecteurs recombines d'administration genique pour traiter ou prevenir des maladies de l'oeil
AU7242796A (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
AU4559300A (en) Use of phyllanthus for targeted stimulation of the immune system
ATE306938T1 (de) Verwendung von cpg als adjuvans für hivimpstoff
CA2169297A1 (fr) Vaccins a base de cochleate proteique ou peptidique et procedes d'immunisation faisant appel a ces vaccins
WO2002040059A3 (fr) Procedes et compositions pour induire des reponses immunitaires a mediation cellulaire
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
CA2272407A1 (fr) Procede et compositions destines a stimuler une reponse immunitaire a l'egard d'un antigene de differenciation au moyen d'un antigene de differenciation altere
EP0712926A3 (fr)
AU2002319501A1 (en) Materials and methods relating to improved vaccination strategies
WO1999012951A8 (fr) Utilisations de la nicotinamide adenine dinucleotide et de ses analogues dans le traitement des affections malignes et des maladies infectieuses
WO2001079276A3 (fr) Antigenes de la leishmania servant au traitement et au diagnostic de la leishmaniose
WO1999024077A3 (fr) Compositions et procedes d'administration ciblee de facteurs
MXPA02005506A (es) Clonacion de un gen que codifica una racemasa de aminoacido derivada de tripanosoma cruzi, y usos del mismo.
BR9815496A (pt) Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载